MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Taipei Shuang-Ho Hospital in Taiwan on the publication of groundbreaking findings with MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight's i : X® device in the treatment of deep sternal wound infections (DSWIs), showing significant improvement in patient outcomes, in addition to cost savings and reduced burden on the healthcare system.

The pivotal study, titled “Effects of Adjuvant Hyperbaric Oxygen Therapy and Real-Time Fluorescent Imaging on Deep Sternal Wound Infection: A Retrospective Study,” published in the Journal of Wound Care (2025), found that incorporating MolecuLight real-time fluorescent imaging into the treatment protocol for DSWI led to faster resolution of infection, dramatically reduced antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications such as reinfection and osteomyelitis compared to standard of care hyperbaric oxygen therapy (HBOT).

"This study demonstrates that MolecuLight offers tangible benefits in clinical wound management and is also a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real-time allows us to more effectively guide junior physicians in understanding critical principles of infection control and intraoperative wound assessment. Going forward, we plan to further utilize this technology to improve clinical decision-making and comprehensive patient care," said Dr. Shun-Cheng Chang , study author from Shuang-Ho Hospital.

"We are proud to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," said Wei-Pin Hsieh , CEO of Healtdeva Company Ltd. "This innovation provides physicians with a more efficient and accurate tool for assessing infections, opening up new diagnostic vistas in complex wound management and post-operative care. We strongly believe this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs."

This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real time and guide targeted interventions, is gaining traction among surgeons seeking to optimize outcomes and better manage postoperative complications in a variety of surgical procedures, including the treatment of deep sternal wound infections (DSWIs).

“We would like to congratulate the researchers for their excellent work in this study,” said Anil Amlani, CEO of MolecuLight. “These compelling results further confirm the significant clinical and economic value of MolecuLight’s technology, not only in chronic wound care, but also in critical surgical applications. This study, coupled with our increasing adoption in surgical settings, reflects the growing recognition of our ability to provide crucial, real-time information that empowers clinicians to make better decisions at the point of care, thereby improving patient outcomes and reducing the burden of postoperative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan.”